Neuropathological correlates of psychiatric disorders in PD
Objective: To test the hypothesis that neuropsychiatric symptoms (NPS) in PD are associated with histopathologically confirmed neuronal loss and gliosis (NLG) in the locus coeruleus…Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis
Objective: To evaluate the differential antipsychotic effect of pimavanserin, a selective serotonin (5-HT2A) receptor inverse agonist, for Parkinson’s disease psychosis with and without concomitant anti-dementia…Suicide attempts, suicidal and death ideation in Parkinson’s disease
Objective: The objective of this study was to assess the correlates of suicidal and death ideation and suicide attempts in patients with parkinson’s disease. Background:…Baseline Clinical Predictors of Future Psychotic Symptoms in de novo Parkinson Disease
Objective: To determine which baseline clinical symptoms are associated with future psychotic symptoms in de novo Parkinson disease (PD). Background: Because psychosis in PD is…Predictors of onset of psychosis in Parkinson’s disease: “Who gets it early?”
Objective: To explore the factors which may predict the onset of psychosis in Parkinson’s disease (PD). Background: Non-motor symptoms (NMS) are commonly observed in PD.…Treatment of Parkinson’s disease psychosis–a systematic review of RCTs
Objective: An SLR was conducted to assess the evidence from RCTs supporting the safety and efficacy of Parkinson’s disease psychosis (PDP) treatments. Background: PDP is…Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis
Objective: Our objective was to determine whether psychosis in non-demented Parkinson’s disease (PD) patients is associated with domain-specific cognitive impairment on the Mini-Mental State Exam…Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice
Objective: To examine if actual clinical practice of antipsychotic use in Parkinson's Disease patients are consistent with published evidence-based reviews of treatment recommendations and discuss…Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment
Objective: A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis…A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations. Background: Nelotanserin is a selective 5HT2A receptor inverse…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »